Neurocrine gets FDA approval for 'sprinkle' Ingrezza

The U.S. Food and Drug Administration (FDA) has greenlit a new oral granules formulation of Ingrezza by Neurocrine Biosciences. This new version aims to assist those affected by movement disorders such as tardive dyskinesia and chorea associated with Huntington's disease.

Ingrezza's new Sprinkle capsules offer a convenient alternative for individuals who have trouble swallowing pills. The granules can be easily added to food, making it easier for patients to adhere to their treatment regimen.

Both tardive dyskinesia and chorea are serious movement disorders. Tardive dyskinesia involves uncontrollable, repetitive movements of the face and other body parts. It is frequently linked to the prolonged use of certain mental health medications. On the other hand, chorea is an involuntary movement disorder found in most individuals with Huntington's disease, affecting motor coordination, walking, swallowing, and even speech.

In 2017, Ingrezza, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, made history as the first FDA-approved treatment for adults with tardive dyskinesia. The drug expanded its scope in 2023 when it received approval for treating chorea associated with Huntington's disease.

The introduction of Ingrezza's Sprinkle capsules represents a significant advancement in managing these debilitating conditions. Patients struggling with swallowing difficulties now have a user-friendly option, ensuring they maintain their medication schedules more effectively. This development underscores Neurocrine Biosciences' commitment to improving the quality of life for those grappling with these challenging movement disorders.